KR100954216B1 - Composition for treating atopic dermatitis comprising agents inhibiting immune response of type Th1 and type Th2 - Google Patents

Abstract

The present invention inhibits Th1 and Th2 immune responses acting at each stage of atopic dermatitis, and also inhibits NF-kB involved in acute acute inflammatory reactions, thereby providing a composition for treating atopic dermatitis having no side effects and excellent efficacy. do. More specifically, it provides a composition characterized in that it comprises at least one selected medicinal herbs to include essentially ume from the group consisting of ume, creation, ginseng, horse riding.

Atopic dermatitis, ume, creation, red ginseng, horse riding, Th1, Th2, NF-kB

Description

Composition for treating atopic dermatitis comprising agents inhibiting immune response of type Th1 and type Th2}

The present invention relates to an immune response and inflammation control composition that simultaneously inhibits helper type T1 (Th1) and helper type T2 (Th2) immune responses, and inhibits NF-kB activity, and particularly for the prevention, improvement or treatment of atopic dermatitis. It relates to a composition.

Atopic dermatitis is a disease that occurs in people with allergic atopic dermatitis, and itching has very severe eczema, thick, rough skin, and recurrent chronic dermatitis. With the recent increase in environmental pollutants, the number of patients with atopic dermatitis is increasing day by day, and about 20% of children suffer from atopic dermatitis. The incidence of skin immune diseases in Korea has been increasing every year. For example, as of 2004, more than 1.2 million people visited the hospital due to atopic dermatitis. Accounted for 18%. Atopic dermatitis is known to be involved in genetic, immunological and environmental factors.

Atopic dermatitis is mostly caused by an immune mechanism associated with IgE, and there are many reports that an immune response caused by T cell abnormality is involved, and the role of helper T cells (Th cell) is known to be important. Helper T cells include helper T1 (Th1) cells and helper T2 (Th2) cells. Cytokines secreted by Th1 cells are involved in cell-mediated immune responses, and cytokines secreted by Th2 cells are responsible for antibody immune responses. Many T cells are found in atopic dermatitis lesions, and cytokines secreted by Th2 cells play an important role in the development of atopic dermatitis. IL-4 and IL-13 secreted by Th2 cells promote IgE production, and IL-5 enhances basophils (International Immunology 2004, 16 (8), p1155-1160).

In addition to Th2 cell secreting cytokines, interferongamma, a Th1 cell secreting cytokine, plays an important role in atopic dermatitis (Journal of Clinical Investigation 1999, 103 (8), p1103-1111). It is reported that the immune response varies according to the development of atopic dermatitis, Th2 cells are involved in acute atopic dermatitis, and Th1 is involved in chronic atopic dermatitis. In other words, IL-4 and IL-3, which are secreted from Th2, play an important role. Thitch cells increase when itching begins to scratch (Journal of Clinical Investigation 2004, 113, pp651-657). According to Leung et al., Atopic dermatitis caused by house dust mite allergens progresses in two stages, the initial stage of which mainly produces IL-4 by Th2 cells, and interferon gamma by Th1 cells after 24-48 hours ( Lancet 2003, 361, p151-160). Therefore, in order to effectively prevent, treat or improve atopic dermatitis, a substance or composition capable of affecting both Th1 and Th2 cells and inhibiting production of IL-4 and interferon gamma may be effective.

NF-kB acts on the gene expression mechanism that causes inflammation, tumor necrosis factor (TNF), interleukin-1 (IL-1), IL-6, IL-8, GM-CSF, inducible It is known as a transcription factor that increases the expression of nitric oxide synthase (iNOS), intercellular adhesion molecule 1 (ICAM-1), E-selectin, MHC class I and II molecules. Therefore, the regulation of NF-kB activity can be usefully used for the treatment of chronic and acute inflammatory diseases, and the NF-kB inhibitor may have an atopic dermatitis therapeutic effect.

As therapeutic agents for atopic dermatitis, cyclosporin A, FK-506, a steroid compound, etc., which are immunosuppressive agents, are used. However, cyclosporin A has serious side effects such as hypertension, nephrotoxicity, and drug interactions. Steroid-based substances are extremely limited to use in addition to medicines due to serious side effects. Indeed, the market size of steroid-based atopy drugs, which are generally widely used, continues to shrink due to their high side effects. FK-506 is known to be concerned about hormonal disturbances. Therefore, in order to eliminate these side effects and develop a new drug with excellent efficacy, it is necessary to search for and develop a new atopy improver.

Therefore, the development of the composition for the treatment of atopy as a natural medicine has been attempted, Moonjuran extract (Korean Patent Publication No. 10-2007-0003365), juniper extract (Registration No. 10-0614676), Goat milk extract (Registration Patent No. 10- 0719761) has been reported, and there is a composition (Registration No. 10-0682048) containing a number of medicines, such as live yellow, vigor, mold opening, windproof, creation, cheongung, etc., but it is effective and simultaneously inhibits Th1 and Th2 cells In addition, no research has been conducted on medicinal herbs having NF-kB inhibitory effects.

In the present invention, by inhibiting the Th1 and Th2 immune response acting at each stage of atopic dermatitis, and also inhibits NF-kB involved in acute acute inflammatory reaction, develop a composition for treating atopic dermatitis with no side effects and excellent efficacy It aims to do it.

In order to solve the above problems, the present invention provides a composition comprising one or more selected medicinal herbs, which essentially comprises ume from the group consisting of ume, creation, ginseng, horse riding.

The composition according to the present invention has an immunomodulatory ability to inhibit the production of IL-4 and interferon gamma, and an inflammation inhibitory ability to inhibit the production of NF-kB, which is the most important factor of cell inflammation, to prevent, treat, and treat excellent atopic dermatitis. It can be used as a composition for improvement.

As described above, the present invention is a composition for the prevention, treatment, improvement of atopic dermatitis, characterized in that it comprises at least one selected medicament essentially comprising a mae from the group consisting of ume, creation, ginseng, horse riding It is about. The present invention also relates to pharmaceuticals, quasi-drugs, food, and cosmetics comprising the composition. The inventors of the present invention screened about 200 herbal medicines in order to find herbal medicines that inhibit Th1 and Th2 immune responses that act on each stage of atopic dermatitis and also inhibit NF-kB, which is involved in acute inflammatory reactions. As a result, it has been found that ume, generation, ginseng, horse riding have this effect, and came to complete the present invention.

Ome (烏梅) refers to the peeling of unripe plums and darkened with straw smoke, which has been used as an antibacterial and hemostatic agent. Dongbogam describes omae as a medicine that eliminates thirst and sputum, stops vomiting and diarrhea, and dissolves alcohol. Omae is enhanced by external heating like red ginseng, which is not produced by the plum itself. It has been reported that the hawk has an inhibitory effect on the urease activity of Helicobacter pylori (Unexamined Patent Publication No. 10-2006-0040254).

Creation is the long root of the shovel which is trimmed and dried Shochu is widely known as a herb that can be long and disease-free.

Ginseng (Sophora flavescens Ait.) Is a grass that grows in the foothills or sunny meadows of the legumes, on the grassland, plains, roadsides, sandy soils, and sunny ocher soils. The therapeutic effect is called ginseng because it has the same effect as ginseng and bitter taste. Bacterial dysentery, acute gastroenteritis, acute infectious hepatitis, pediatric pneumonia, acute tonsillitis, chronic bronchitis, intestinal trichomoniasis, trichomoniasis vaginitis, ascites caused by schistosomiasis, lamblia intestinalis, insecticidal, hemolysis, diuresis, crop pest control, skin worm parasite Remedies, athlete's foot, sweat, malignant boils, appetite promotion, dehumidification, dream tablets, oil wells, bowels, caries, rectal ulcers, jaundice, acute tonsillitis, leprosy, constipation, erosion, prolapse, itching, swelling caused by mange It is used in Korean medicine for a wide range of diseases, such as efficacy in burns and burns.

Horse riding is used as an antipyretic and belongs to the family of Mia family.

However, it is not known that these or combinations thereof can inhibit Th1 and Th2 cytokines and treat atopic dermatitis by inhibiting NF-kB.

The inventors of the present invention, through the experiment using immune cells, berry, production, ginseng, horse riding and mixtures thereof inhibit interferon-gamma, IL-4 and NF-kB, and the activity is commercialized as anti-inflammatory (botanpi) ) Or greater than cyclosporin (FIGS. 1, 3 and 5). In particular, the activity of the umeru was better, which was surprisingly large compared to the activity of the plum (Fig. 2 and 4). This activity of maeja appeared to treat atopic dermatitis in clinical trials (Fig. 7).

Based on the experimental results, the present invention provides the following items.

[1] composition for treating or improving atopic dermatitis, comprising at least one selected medicinal herb from the group consisting of ume, generation, ginseng and horse riding.

[2] The composition of [1], wherein the medicines are included in the form of an extract using a solvent selected from the group consisting of water, ethanol, butanol, ethyl acetate, hexane, and mixtures thereof.

[3] The composition of [1], which is administered orally.

[4] The composition of [1], which is applied to the skin.

[5] A pharmaceutical product comprising the composition of any one of [1] to [4].

[6] An quasi drug containing the composition of any one of [1] to [4].

[7] A food comprising the composition of any one of [1] to [3].

[8] A cosmetic comprising the composition of any one of [1], [2] and [4].

The herbal medicine contained in the composition for treating atopic dermatitis according to the present invention may be contained in the composition in various forms. For example, the herbal medicine may be completely dried and then finely powdered, or extracted with a solvent to be included in the composition. Water or ethanol as solvent Methanol, butanol, ethyl acetate, hexane and mixtures thereof may be used, but is not limited thereto. In the case of a mixed solvent, for example, water: ethanol is mixed at 20%: 80% to 99%: 1% Can be used but is not limited to this. Extraction methods for extracting the herbal medicines of the present invention include a cold leaching method for leaching at a relatively low temperature for a predetermined time, a warm leaching method for leaching at 35-45 ^o C, a heat extraction method for leaching at 60-120 ^o C, percolater ), Distillation cooling extraction, etc. may be used, but is not limited thereto. The extracts of the herbal medicines may be extracted individually by a conventional method, or all at once after mixing the herbal medicines. If necessary, it can be concentrated and powdered.

The composition according to the present invention may further contain pharmaceutically, food or cosmetically acceptable ingredients in addition to the herbal ingredients. For example, binders, lubricants, disintegrants, excipients, solubilizers, stabilizers, bases, lubricants, preservatives, wetting agents, emulsifiers, suspending agents, viscosity regulators, preservatives, surfactants, antioxidants, moisturizers, fragrances, pigments, etc. It may further contain. In addition, it may further contain a moisturizer such as ceramide or a lipid component, a steroid such as hydrocortisone, a vitamin A derivative such as retinyl palmitate, tocopepol, and other plant extracts, which have been frequently used in conventional atopic skin treatments. The composition of the present invention can be applied orally or topically, tablets, powders, capsules, granules, pills, solutions, suspending agents, ointments, creams, lotion type, lotion type, pack type and the like, as well as soap, face wash It can be manufactured in various forms such as face washes such as foams. It is also possible to make liposomes.

The dosage of the composition according to the present invention can be appropriately adjusted according to the weight, age, sex, health status, digestive status, etc. of the person to which it is applied, and a typical single dosage can be administered at 0.1mg to 100mg per kg of body weight. have. When the composition of the present invention is prepared in the form of an external preparation applied to the skin, the blending amount of the herbal extract in the external preparation for skin may be 0.05% to 50.0% by weight of the total, preferably 0.1 to 10.0% by weight.

The composition of the present invention can be used in various quasi-drugs for the prevention and alleviation of atopic dermatitis. In addition, the composition of the present invention can be used in a variety of foods for the prevention and reduction of atopic dermatitis. The composition of the present invention can be applied to any formulation that can be taken as a food, and examples thereof include powders, granules, tablets, pills, capsules, soft capsules, or liquids. Examples of the food to which the composition of the present invention can be added include, for example, various foods, meats, beverages such as tea, snacks, confectionery, ramen, other noodles, candy, chocolate, ice cream, gum, vitamin complex, and health. Functional foods;

Hereinafter, the present invention will be described in more detail with reference to examples and the like, but embodiments according to the present invention can be modified in many different forms and the scope of the invention is not limited thereto.

Experimental Example  One: Herbal medicine  Preparation of Sample

After selecting about 200 kinds of herbal medicines and cutting them, 50 ml of 70% alcohol was added to each 10g of herbal medicines, and extracted at 4 ^o C for 21 days. Thereafter, a supernatant was collected by using a centrifuge (3000 rpm, 5 minutes), which was used as a sample stock solution, and serially diluted to prepare a sample for sample retrieval.

Experimental Example  2: mouse Splenocyte  extraction

Mouse spleen cells were extracted by the following method. The mouse is cervical distal bone, sterilized with alcohol and incised abdomen, and the spleen is aseptically collected. After collection, put in antibiotic-added RPMI-complete media and refrigerate. Approximately 2 ml of animal cell medium (RPMI media) is added per spleen and the spleen is completely ground. Red blood cells are removed by treatment with 0.84% ammonium chloride solution for 10 seconds. Stop the erythrocyte hemolysis reaction with the medium, and then settle the cells after centrifugation. The obtained cell fraction was used for the experiment after incubation for one day.

Experimental Example  3: interferon-gamma Assay

Phytohemagglutinin (PHA) Stock Solution was prepared by dissolving 0.5 mg of PHA per 1 ml of sterilized phosphate buffer solution PBS.

PMA Stock Solution was prepared by dissolving 100 ug of PMA per mL of DMSO.

Cyclosporin Stock Solution was prepared by dissolving 1 mg of cyclosporin per 1 ml of ethanol, and the stock solution of the extract of the herbaceous extract and the herbal medicine of the present invention was used as a sample stock solution prepared in Experimental Example 1.

2.5 ml of Jurkat cell culture, mouse splenocytes, EL-4 cell line (1 x 10 ⁶ cells / ml, 1 x 10 ⁷ cells / ml, 5 x 10 ⁶ cells / ml) and 2.5 ml of medium (RPMI 1640 + 10) 10 ml / L penicillin-streptomycin) containing% fetal calf serum was incubated in a 25T flask. After dispensing 150 ul of the cell culture solution into 96 wells, 15 ul of PHA stock solution was added and 15 ul of medicinal stock solution was added at the same time. After 18 hours of incubation, the supernatant was centrifuged and analyzed for cytokines on the day by ELISA.

The ELISA method was used to measure the Th1 cytokine interferon-gamma (IFN-γ). BIOSOURCE's IFN-γ immunoassay kit was used. Each well of a 96-well plate was coated with capture antibody of IFN-γ. Thereafter, 100 ul and 50 ul of Incubation Buffer were added to the appropriately diluted cell culture supernatant, and 50 ul of biotinylated detection antibody (Biotin Conjugate) solution was added thereto and left at room temperature for 2 hours. After completely removing the solution and washing four times, add 100 ul of Streptavidin-HRP Working Solution, and leave it at room temperature for 30 minutes. Completely remove the solution and wash. 100 ul of Stabilized Chromogen was added and allowed to stand at room temperature for 30 minutes. Then, 100 Stop Solution was added and data were read at 450 nm.

Figure 1 shows the IFN-gamma inhibition rate of herbal extracts. Inhibitory effect on bark skins in buckwheat, red ginseng, horseback riding, creation, and mixtures thereof (oil: creation: red ginseng: horseback riding = 4: 1: 1: 2) compared to the bark skins currently used as anti-inflammatory agents Saenghwanghwang, mold opening, windproof, gardenia, gold and silver flower had lower inhibitory activity than bark skin.

In particular, ume was about 6 times higher in inhibition rate of interferon-gamma than plum (Fig. 2). It is presumed to be due to a new substance that is produced in the process of making plums errant.

Experimental Example  4: IL -4 Assay

An ELISA method was used to measure Interleukin-4 (IL-4), a Th2 cytokine in the cell culture of Experimental Example 3. BIOSOURCE's immunoassay kit was used and WHO reference preparation 86/504 (NIBSC, Hertfordshire, UK, EN6 3QG) was observed. Values of representative candidates among extracts of about 200 kinds of herbal medicines are shown (FIG. 3).

Groups of substances that effectively inhibit IL-4 are mae, generation, gosam, horse riding, and mixtures thereof (omega: creation: gosam: equestrian = 4: 1: 1: 2), which is better than the typical anti-inflammatory material, bark skin. Inhibition rate is shown. In particular, IL-4 levels were found to be nearly cyclosporine levels. In the case of umeol than normal plum showed a superior efficacy improvement effect (Fig. 4). It is presumed to be due to a new substance that is produced in the process of making plums errant.

Experimental Example  5: NF - kB Assay

To analyze NF-kB, the most important factor in cell inflammation, and to analyze many samples at low cost, an assay using Luciferase was established. This method has a short experimental step, so the data is highly reproducible and many sample materials can be processed simultaneously. As the cell line, NIH3T3-luc cell line of Panomics was used. The preliminary experiments confirmed the expression of NF-kB and the inhibition by each candidate. About 12-17 times of luciferase (NF-kB) was induced by the induction source (TNF-alpha), and it was confirmed that the experimental reproducibility was excellent. NIH3T3 from Panomics (Rev A 060820 Stable Cell Line: NIH3T3 / NFkB-luc 1); Stable Cell Line: NIH3T3 / NFkB-luc was used. The NIH3T3 / NFkB-luc cell line is a system designed to identify cell-based NFkB transcription factors, a cell line in which pNFkB-luc (Panomics P / N LR0051) and pHyg vectors are established through simultaneous transfection. It is selected using hygromycin separation method using the property of pHyg. This method inserts the luciferase gene into the cell chromosome. Each medium production method is as follows.

Put 15 mL of pre-warmed Growth medium in a 100-mm culture dish or T-75 flask, and add the cell line to the prepared culture dish to disperse the cell line well. Place the culture dish in a humidified 37 ^° C. (5% CO ₂ ) incubator and change the medium every 2-3 days. Once the 90% confluency is reached, create a stock to cryopreserve and continue incubating. Cells are cultured according to passage method to preserve cell lines.

NF-kB measurement was performed as follows. Dispense the cells into a 12-well plate at 5 x 10 ⁵ / well level in Initial Growth Media, and incubate for 24 hours in moistened 5% CO ² (37 ^o C) to allow cell lines to adhere to the bottom. Replace with fresh medium that does not contain Serum. After incubating in 5% CO ² (37 ^o C) incubator for about 8 hours, the medium is removed and 100 ul lysis buffer is added to each well to measure Luciferase activity. For the measurement method, please refer to the Promega manual. (Promega P / N E1500)

NF-kB quantification using 96-Well was carried out with trypsin-treated cell lines at 5 x 10 ⁴ cells / 100 ul and placed in 96-well plates. Put ul together. Incubate overnight in a 5% CO ² incubator set at 37 ^o C, treat NF-kB-derived medicinal products (eg TNF-alpha at 15 ul volume level, remove media and remove 50 ul lysis buffer (Promega P / N E1500 Process each well at room temperature for 2 minutes with Lysis buffer and check if Lysis Buffer is sufficiently dissolved After rapid freezing at 0 ^o C, melt at room temperature and mix solution 2 ~ 3 times 20 ul of each lysate was transferred to a new 96-well, 20 ul of luciferase substrate was added to each well and mixed 2-3 times, and measured using a Luminometer.

The quantitative results of NF-kB (Luciferase assay) were compared by diluting Botanpi and cyclosporin (CsA) commercially available with each herbal extract. The induction rate by induction source was 19.44 times, and high ginseng, production, horseback riding, and buckwheat showed high NF-kB inhibition rate. They showed higher inhibition rate than cyclosporin, and showed better NF-kB inhibition than Botanpi in berry, production, and horse riding compared to Botanpi, which is known to have high anti-inflammatory activity. Inhibitory activity was shown (FIG. 5).

Experimental Example  6: Activity comparison by extraction solvent

The extracts of five plums, wild ginseng, red ginseng and horse riding were extracted with water, 70% ethanol and 100% ethanol, respectively, and the IL-4 inhibition rate of each extract was measured to compare the activities. 70 ~ 100% Ethanol for buckwheat, 70% Ethanol for horseback riding, 100% Ethanol for ginseng, and 70 ~ 100% Ethanol for generation showed higher IL-4 inhibition rate. It could be confirmed (Fig. 6).

Experimental Example  7: Evaluation of the therapeutic effect of atopic dermatitis on omega

100 ul of maeol extract using 70% ethanol was applied to the site of atopic dermatitis once a day for 3 weeks. Figure 7 is a photograph before and after the treatment evaluation experiment of atopic dermatitis using the ume extract. As shown in the picture, the mae extract of the present invention can be seen that the excellent efficacy in the treatment of atopic dermatitis.

Production Example : cream

1) fruit extract 1.0% by weight

2) 1.0% by weight of creation extract

3) stearic acid 2.0% by weight

4) stearyl alcohol 3.0 wt%

5) 1,3 butylene glycol 5.0 wt%

6) 4.0 wt% glycol monostearate

7) Potassium hydroxide 0.1% by weight

8) Purified water 77.9 wt%

9) Lecithin 5.0% by weight

10) Cholesterol 1.0 wt%

The oil and water components were heated to 75 ^° C., respectively, and then emulsified using a homogenizing mixer in a cream manufacturing mixer, followed by degassing, filtration and cooling to prepare a cream.

Production Example : Lotion

1) Oil Extract 0.1% by weight

2) 1,3-butylene glycol 8.0% by weight

3) glycerin 2.0% by weight

4) Xanthan gum 0.02 wt%

5) citric acid 0.01% by weight

6) Sodium Citrate 0.1% by weight

7) Ethanol 5.0 wt%

8) 0.1% by weight of methyl paraoxybenzoate

9) 0.1% by weight of polyoxyethylene hardened castor oil (40E.O.)

10) fragrance 0.1 wt%

11) 84.47 wt% of purified water

The components 1-6, 11, and 7-10 were melt | dissolved uniformly, respectively, and both were mixed and filtered.

Production Example : Ointment

1) Oil Extract 1.0% by weight

2) Creation extract 1.0 wt%

3) Polyoxyethylene Cetyl Ether (30 E.O.) 2.0 wt%

4) 10.0% by weight glycerin monostearate

5) 5.0 wt% of liquid paraffin

6) cetanol 6.0% by weight

7) 10.0 wt% propylene glycol

8) 0.1% by weight of methyl paraoxybenzoate

9) Purified water 64.9 wt%

Mix components 3-6 by dissolution by heating, and make oily phase at 70 ^° C. Components 1, 2 and 7-9 are dissolved by heating, mixed and maintained at 75 ^° C. to form an aqueous phase. Emulsify the oil phase and the water phase together and cool the product to 30 ^o C.

Production Example : Bath Solvent

1) 5.0% by weight of berry extract

2) Sodium bicarbonate 50.0 wt%

3) Yellow 202 0.05% by weight

4) 0.25% by weight fragrance

5) 44.7% by weight of anhydrous sodium sulfate

Mix 1-5 components evenly.

Production Example : beverage

1) fruit extract 1.0% by weight

2) 5.0 wt% citric acid

3) 0.1% by weight fragrance

Water is mixed with components 1-3 to make 100% by weight in total.

Production Example : refine

1) Schisandra extract 2.5% by weight

2) 2.5% by weight of extract produced

3) 2.5% by weight of red ginseng extract

4) Riding extract 2.5% by weight

5) 20.0 wt% per tablet bag

6) carboxymethylcellulose 20.0 wt%

7) 35.0 wt% of microcrystalline cellulose

8) polyvinylpyrrolidone 5.0% by weight

9) Talc 10.0 wt%

After mixing components 1-7, an aqueous solution of component 8 is added as a binder and granulated in a conventional manner. After blending the component 9 as a lubricant, it tablets by tablet.

Figure 1 shows the IFN-gamma inhibition rate of herbal extracts. 0.14 means 0.14% (V / V) of the sample stock solution in the cell culture solution. The inhibition rate calculation method is as follows.

Inhibition rate = {1- (cytokine production in the sample treatment group / cytokine production in the positive control group)} x 100

Figure 2 compares the inhibition rate of IFN-gamma of ume and plum extract.

Figure 3 shows the inhibition rate of IL-4 of the herbal extracts. The inhibition rate is calculated as follows.

Inhibition rate = {1- (cytokine production in the sample treatment group / cytokine production in the positive control group)} x 100

Figure 4 compares the inhibition of IL-4 of the ume and plum extract.

Figure 5 shows the NF-kB inhibitory effect of the herbal extracts.

CsA: cyclosporin, CON: control group administered with induction

The fold of the Y-axis is 1 fold for the amount of NF-kB produced by the negative control group without the induction source.

Figure 6 shows the effect of increasing the IL-4 inhibitory activity according to the extraction solvent.

Figure 7 is a photograph before and after the treatment of the maeru atopic dermatitis site.

Claims (8)

Essentially containing a mae, additionally, at least one selected from the group consisting of ginseng, horse riding as an active ingredient, atopy characterized in that it comprises only as an active ingredient to inhibit the Th1 and Th2 immune response as an active ingredient A composition for treating or improving sexual dermatitis. The composition of claim 1, wherein the medicinal herbs are included in the form of an extract using a solvent selected from the group consisting of water, ethanol, butanol, ethyl acetate, hexane, and mixtures thereof. The composition of claim 1, which is administered orally. The composition of claim 1 which is applied to the skin. A pharmaceutical product comprising the composition of any one of claims 1 to 4. Quasi drug containing the composition of any one of Claims 1-4. Food comprising the composition of any one of claims 1 to 3. Cosmetics comprising the composition of any one of claims 1, 2 and 4.

Images